BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 17888544)

  • 1. ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain.
    Bandaru VV; Troncoso J; Wheeler D; Pletnikova O; Wang J; Conant K; Haughey NJ
    Neurobiol Aging; 2009 Apr; 30(4):591-9. PubMed ID: 17888544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysregulation of sphingolipid and sterol metabolism by ApoE4 in HIV dementia.
    Cutler RG; Haughey NJ; Tammara A; McArthur JC; Nath A; Reid R; Vargas DL; Pardo CA; Mattson MP
    Neurology; 2004 Aug; 63(4):626-30. PubMed ID: 15326233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FTY720 decreases ceramides levels in the brain and prevents memory impairments in a mouse model of familial Alzheimer's disease expressing APOE4.
    Crivelli SM; Luo Q; Kruining DV; Giovagnoni C; Mané-Damas M; den Hoedt S; Berkes D; De Vries HE; Mulder MT; Walter J; Waelkens E; Derua R; Swinnen JV; Dehairs J; Wijnands EPM; Bieberich E; Losen M; Martinez-Martinez P
    Biomed Pharmacother; 2022 Aug; 152():113240. PubMed ID: 35689862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraneuronal amyloid-beta plays a role in mediating the synergistic pathological effects of apoE4 and environmental stimulation.
    Levi O; Dolev I; Belinson H; Michaelson DM
    J Neurochem; 2007 Nov; 103(3):1031-40. PubMed ID: 17666042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimer's disease pathogenesis.
    Zhu L; Zhong M; Elder GA; Sano M; Holtzman DM; Gandy S; Cardozo C; Haroutunian V; Robakis NK; Cai D
    Proc Natl Acad Sci U S A; 2015 Sep; 112(38):11965-70. PubMed ID: 26372964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2.
    Vandal M; Alata W; Tremblay C; Rioux-Perreault C; Salem N; Calon F; Plourde M
    J Neurochem; 2014 May; 129(3):516-26. PubMed ID: 24345162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SREBP-1a polymorphism influences the risk of Alzheimer's disease in carriers of the ApoE4 allele.
    Spell C; Kölsch H; Lütjohann D; Kerksiek A; Hentschel F; Damian M; von Bergmann K; Rao ML; Maier W; Heun R
    Dement Geriatr Cogn Disord; 2004; 18(3-4):245-9. PubMed ID: 15286454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The plant sterol brassicasterol as additional CSF biomarker in Alzheimer's disease.
    Vanmierlo T; Popp J; Kölsch H; Friedrichs S; Jessen F; Stoffel-Wagner B; Bertsch T; Hartmann T; Maier W; von Bergmann K; Steinbusch H; Mulder M; Lütjohann D
    Acta Psychiatr Scand; 2011 Sep; 124(3):184-92. PubMed ID: 21585343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of apolipoprotein E4 (ApoE4) in the pathogenesis of Alzheimer's disease: lessons from ApoE mouse models.
    Huang Y
    Biochem Soc Trans; 2011 Aug; 39(4):924-32. PubMed ID: 21787325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease.
    Cutler RG; Kelly J; Storie K; Pedersen WA; Tammara A; Hatanpaa K; Troncoso JC; Mattson MP
    Proc Natl Acad Sci U S A; 2004 Feb; 101(7):2070-5. PubMed ID: 14970312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced levels of human apoE4 protein in an animal model of cognitive impairment.
    Sullivan PM; Han B; Liu F; Mace BE; Ervin JF; Wu S; Koger D; Paul S; Bales KR
    Neurobiol Aging; 2011 May; 32(5):791-801. PubMed ID: 19577821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes.
    Blanchard JW; Akay LA; Davila-Velderrain J; von Maydell D; Mathys H; Davidson SM; Effenberger A; Chen CY; Maner-Smith K; Hajjar I; Ortlund EA; Bula M; Agbas E; Ng A; Jiang X; Kahn M; Blanco-Duque C; Lavoie N; Liu L; Reyes R; Lin YT; Ko T; R'Bibo L; Ralvenius WT; Bennett DA; Cam HP; Kellis M; Tsai LH
    Nature; 2022 Nov; 611(7937):769-779. PubMed ID: 36385529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease.
    Huang Y
    Trends Mol Med; 2010 Jun; 16(6):287-94. PubMed ID: 20537952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease?
    Katsel P; Li C; Haroutunian V
    Neurochem Res; 2007; 32(4-5):845-56. PubMed ID: 17342407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of parental history of Alzheimer's disease and apolipoprotein E epsilon4 on the BOLD signal during recognition memory.
    Xu G; McLaren DG; Ries ML; Fitzgerald ME; Bendlin BB; Rowley HA; Sager MA; Atwood C; Asthana S; Johnson SC
    Brain; 2009 Feb; 132(Pt 2):383-91. PubMed ID: 18829694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ApoE4 May be a Promising Target for Treatment of Coronary Heart Disease and Alzheimer's Disease.
    Chen W; Jin F; Cao G; Mei R; Wang Y; Long P; Wang X; Ge W
    Curr Drug Targets; 2018; 19(9):1038-1044. PubMed ID: 29623835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High ability of apolipoprotein E4 to stabilize amyloid-β peptide oligomers, the pathological entities responsible for Alzheimer's disease.
    Cerf E; Gustot A; Goormaghtigh E; Ruysschaert JM; Raussens V
    FASEB J; 2011 May; 25(5):1585-95. PubMed ID: 21266538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceramide analog [
    Crivelli SM; van Kruining D; Luo Q; Stevens JAA; Giovagnoni C; Paulus A; Bauwens M; Berkes D; de Vries HE; Mulder MT; Walter J; Waelkens E; Derua R; Swinnen JV; Dehairs J; Mottaghy FM; Losen M; Bieberich E; Martinez-Martinez P
    Sci Rep; 2020 Nov; 10(1):19354. PubMed ID: 33168861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau haplotypes and ApoE4 do not act in synergy on Alzheimer's disease.
    Almos PZ; Horváth S; Czibula A; Raskó I; Domján N; Juhász A; Janka Z; Kálmán J
    Psychiatry Res; 2011 Apr; 186(2-3):448-50. PubMed ID: 20837363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers.
    Chételat G; Fouquet M
    Rev Neurol (Paris); 2013 Oct; 169(10):729-36. PubMed ID: 24016463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.